Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma (MM) in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the
Sundar Jagannath
Philip L. McCarthy
Multiple myeloma (MM) is an incurable disease. One major goal in the treatment of patients with MM is to improve progression-free and overall survival (PFS and OS, respectively). In the past 10 years, the median OS for patients with MM has
Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus and Joanne S. Buzaglo
Background Multiple myeloma (MM), a plasma cell malignancy, is the second most common hematologic cancer in the United States, with an estimated 32,110 new cases occurring in 2019, and an estimated 12,960 deaths. 1 Advances in treatment using
Multiple myeloma will account for an estimated 15,270 (1.1%) new cancer cases in the United States in the year 2004, including 8,090 cases in men (1.2%) and 7,180 (1.1%) cases in women. It will also be responsible for approximately 11,070 (2.0%) cancer deaths in 2004. Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable at present. However, treatment algorithms such as this one (based on published data and clinical experience) can optimize therapy, not only for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.
For the most recent version of the guidelines, please visit NCCN.org
Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre and Natalie S. Callander
Background: Obesity, and in particular severe obesity, is increasingly prevalent in the United States. Epidemiological studies have shown an association in multiple myeloma (MM) between obesity and mortality (Teras et al, Br J Haematol 2014
Kenneth C. Anderson
Multiple myeloma (MM) is an example of a disease that has seen rapid bench-to-bedside translation of novel agents targeting the tumor in its microenvironment, with clinical trials ultimately leading to FDA approval. Remarkably, 16 new treatments
8 8 Suppl_1 Suppl_1 Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics Jagannath Sundar MD 02 2010 8 8 Suppl_1 Suppl_1 S-1 S-1 S-3 S-3 0080S-1 10.6004/jnccn.2010.0111 Complications of
- Feb 2010
Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee and Anaadriana Zakarija
include those of the stomach, kidney, uterus, lung, ovary, bladder, and testis. 1 , 21 , 31 In addition, an increased risk of VTE has been observed in certain hematologic malignancies, such as lymphoma, acute leukemia, and multiple myeloma. 1 , 40 , 41
Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang
Background: The role of panobinostat compared to elotuzumab and ixazomib in patients with multiple myeloma(MM) continues to be debated in the context of its complications. Methods: MedLine and Cochrane databases were queried with different MeSH
Audrey Demaree, Anthony Hewitt, Ben Eckert and Lik Wee Lee
and routine patient management. MRD assessment is now recommended within several lymphoid cancer NCCN guidelines, including multiple myeloma (MM), ALL, and CLL. The clonoSEQ® Assay (Adaptive Biotechnologies; Seattle, WA) is currently the only FDA
